Roth David 4
4 · Syros Pharmaceuticals, Inc. · Filed Aug 2, 2023
Insider Transaction Report
Form 4
Roth David
Chief Medical Officer
Transactions
- Sale
Common Stock
2023-07-31$3.95/sh−7,348$29,025→ 0 total
Footnotes (1)
- [F1]The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 27, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.